SCHEDULE: Ally Bridge Group Discloses 4.6% Stake in Ceribell
Beneficial Ownership Disclosure
Ally Bridge Group and its affiliated entities have disclosed a 4.6% passive beneficial ownership stake in Ceribell, Inc. common stock.
Summary
- Ally Bridge Group, through various affiliated entities including ABG WTT-Ceribell Limited and ABG V-Ceribell Limited, beneficially owns 1,691,267 shares of Ceribell, Inc. Common Stock.
- This ownership represents 4.6% of Ceribell, Inc.'s outstanding Common Stock, based on 37,095,690 shares as of October 31, 2025.
- The reporting persons, including Fan Yu, share both voting and dispositive power over all 1,691,267 shares.
- The securities were not acquired and are not held for the purpose of changing or influencing the control of Ceribell, Inc., nor in connection with any transaction having that purpose, other than activities solely related to a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: This is a factual disclosure of beneficial ownership and does not contain information that would inherently suggest positive or negative sentiment regarding the company's performance or prospects.
Future Outlook
NA
Industry Context
This filing indicates a significant, albeit passive, investment by a global life science capital group in Ceribell, Inc., a company likely operating in the life sciences or medical technology sector. Such disclosures are common for institutional investors taking positions in publicly traded companies.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, confirming a passive investment approach.
Key Dates
| Date | Description |
|---|---|
| 12/09/2024 | Date of event which requires the filing of this statement |
| 10/31/2025 | Date as of which the number of outstanding shares of Common Stock of the Issuer was reported on Form 10-Q |
| 11/04/2025 | Date the Issuer's Form 10-Q was filed, reporting outstanding shares |
| 12/11/2025 | Date of filing of this Schedule 13G |
Keywords
Ceribell Inc., Ally Bridge Group, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Passive Investment, Life Science Capital
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.